Author:
Jain Sourabhkumar,Dudhat Kiran,Soniwala M. M.,Kotadiya Nirav,Mori Dhavalkumar
Funder
SSIP-Government Of Gujarat
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science
Reference45 articles.
1. Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of “me-too” HIV-1 integrase inhibitors. Retrovirology. 2009;6(1):1–14.
2. Krishna R, Rizk ML, Larson P, Schulz V, Kesisoglou F, Pop R. Single-and multiple-dose pharmacokinetics of once-daily formulations of raltegravir. Clin Pharm Drug Dev. 2018;7(2):196–206.
3. Saal C, Becker A. Pharmaceutical salts: a summary on doses of salt formers from the Orange Book. Eur J Pharm Sci. 2013;49(4):614–23.
4. Gigante V, Pauletti GM, Kopp S, Xu M, Gonzalez-Alvarez I, Merino V, et al. Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. ADMET and DMPK. 2021;9(1):23–39.
5. Cattaneo D, Baldelli S, Cerea M, Landonio S, Meraviglia P, Simioni E, et al. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother. 2012;56(12):6132–6.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献